AMICUS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.28 USD | +1.08% |
|
-3.11% | -27.55% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,482 | 6,017 | 3,218 | 3,430 | 4,161 | 3,045 | - | - |
| Enterprise Value (EV) 1 | 2,179 | 5,923 | 3,125 | 3,529 | 4,263 | 3,184 | 3,069 | 2,517 |
| P/E ratio | -6.58 x | -21.6 x | -12.6 x | -14.9 x | -27.8 x | -1,694 x | 26.5 x | 10.3 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 13.6 x | 23.1 x | 10.5 x | 10.4 x | 10.4 x | 5.76 x | 4.47 x | 3.34 x |
| EV / Revenue | 12 x | 22.7 x | 10.2 x | 10.7 x | 10.7 x | 6.02 x | 4.51 x | 2.76 x |
| EV / EBITDA | -7.28 x | -24.9 x | -15.6 x | -17.1 x | -61.5 x | 67 x | 14.1 x | 6.49 x |
| EV / FCF | -8.06 x | -25 x | -15.1 x | -20.7 x | -55.7 x | 20.9 x | 13.2 x | 8.44 x |
| FCF Yield | -12.4% | -3.99% | -6.6% | -4.83% | -1.8% | 4.79% | 7.57% | 11.8% |
| Price to Book | 5.22 x | 21.1 x | 10.5 x | 27.9 x | 26.1 x | 9.27 x | 5.03 x | 3.31 x |
| Nbr of stocks (in thousands) | 254,810 | 260,588 | 278,646 | 280,945 | 293,257 | 296,176 | - | - |
| Reference price 2 | 9.740 | 23.09 | 11.55 | 12.21 | 14.19 | 10.28 | 10.28 | 10.28 |
| Announcement Date | 3/2/20 | 3/1/21 | 2/24/22 | 3/1/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 182.2 | 260.9 | 305.5 | 329.2 | 399.4 | 529 | 680.8 | 911.2 |
| EBITDA 1 | -299.3 | -238.2 | -200.2 | -206.8 | -69.34 | 47.54 | 217.8 | 388 |
| EBIT 1 | -304 | -247 | -206.4 | -212.1 | -77.21 | 40.07 | 161.5 | 347 |
| Operating Margin | -166.84% | -94.68% | -67.57% | -64.43% | -19.33% | 7.58% | 23.72% | 38.08% |
| Earnings before Tax (EBT) 1 | -355.9 | -274.3 | -241.6 | -242 | -150.1 | -3.009 | 126.4 | 317.2 |
| Net income 1 | -356.4 | -276.9 | -250.5 | -236.6 | -151.6 | -1.477 | 120.1 | 262.3 |
| Net margin | -195.56% | -106.12% | -81.98% | -71.85% | -37.96% | -0.28% | 17.63% | 28.78% |
| EPS 2 | -1.480 | -1.070 | -0.9200 | -0.8200 | -0.5100 | -0.006070 | 0.3876 | 0.9946 |
| Free Cash Flow 1 | -270.4 | -236.5 | -206.4 | -170.3 | -76.53 | 152.5 | 232.5 | 298.2 |
| FCF margin | -148.39% | -90.66% | -67.55% | -51.74% | -19.16% | 28.83% | 34.14% | 32.73% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 320.75% | 106.73% | 76.85% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 193.62% | 113.71% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 3/1/21 | 2/24/22 | 3/1/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 79.54 | 82.15 | 78.72 | 80.73 | 81.69 | 88.1 | 86.27 | 94.5 | 103.5 | 115.1 | 111.2 | 124.9 | 139.1 | 155.5 | 144.7 |
| EBITDA 1 | -40.88 | -70.63 | -67.31 | -59.28 | -32.55 | -41.02 | -36.38 | -16.65 | -14.8 | -1.51 | -14.35 | -3.697 | 7.425 | 25.99 | - |
| EBIT 1 | -42.4 | -72.15 | -75.34 | -60.61 | -33.84 | -42.33 | -37.64 | -18.86 | -17.02 | -3.692 | -8.679 | 4.211 | 15.68 | 28.86 | 15.88 |
| Operating Margin | -53.3% | -87.82% | -95.71% | -75.08% | -41.42% | -48.05% | -43.63% | -19.96% | -16.45% | -3.21% | -7.81% | 3.37% | 11.28% | 18.56% | 10.98% |
| Earnings before Tax (EBT) 1 | -50.48 | -80.3 | -81.45 | -61.25 | -29.26 | -70.08 | -53.22 | -40.52 | -24.7 | -31.66 | -18.47 | -6.056 | 9.094 | 21.9 | 4.713 |
| Net income 1 | -50.29 | -83.28 | -85.26 | -62.16 | -33.29 | -55.86 | -52.93 | -43.23 | -21.58 | -33.84 | -19.69 | -7.394 | 7.044 | 20.64 | 4.713 |
| Net margin | -63.23% | -101.37% | -108.31% | -76.99% | -40.75% | -63.41% | -61.36% | -45.75% | -20.85% | -29.41% | -17.71% | -5.92% | 5.06% | 13.27% | 3.26% |
| EPS 2 | -0.1900 | -0.2900 | -0.3000 | -0.2100 | -0.1200 | -0.1900 | -0.1800 | -0.1500 | -0.0700 | -0.1100 | -0.0644 | -0.0222 | 0.0189 | 0.0633 | 0.0140 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 2/24/22 | 5/9/22 | 8/4/22 | 11/7/22 | 3/1/23 | 5/10/23 | 8/8/23 | 11/8/23 | 2/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 98.4 | 102 | 139 | 24.3 | - |
| Net Cash position 1 | 303 | 94 | 93.1 | - | - | - | - | 527 |
| Leverage (Debt/EBITDA) | - | - | - | -0.4758 x | -1.466 x | 2.924 x | 0.1116 x | - |
| Free Cash Flow 1 | -270 | -237 | -206 | -170 | -76.5 | 153 | 232 | 298 |
| ROE (net income / shareholders' equity) | -87% | -72.6% | -84.4% | -110% | -107% | -1.44% | 35.8% | 36% |
| ROA (Net income/ Total Assets) | -43.5% | -31.9% | -28% | -29% | -5.13% | 17% | 29% | - |
| Assets 1 | 820.1 | 868.4 | 895.8 | 814.7 | 2,957 | -8.671 | 413.5 | - |
| Book Value Per Share 2 | 1.870 | 1.090 | 1.100 | 0.4400 | 0.5400 | 1.110 | 2.040 | 3.110 |
| Cash Flow per Share 2 | -1.040 | -0.9000 | -0.7500 | -0.5800 | -0.2300 | 0.1800 | 0.6100 | - |
| Capex 1 | 20 | 3.23 | 3.88 | 3.77 | 7.44 | 5.22 | 5.13 | 7.18 |
| Capex / Sales | 10.98% | 1.24% | 1.27% | 1.14% | 1.86% | 0.99% | 0.75% | 0.79% |
| Announcement Date | 3/2/20 | 3/1/21 | 2/24/22 | 3/1/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
10.28
USD
Average target price
18.78
USD
Spread / Average Target
+82.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.55% | 3.04B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- FOLD Stock
- Financials Amicus Therapeutics, Inc.
